Bioequivalence Clinical Trial
Official title:
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil/Hydrochlorothiazide 40 mg/25 mg Film-Coated Tablets in Healthy Adult Subjects / Fasting State
This single dose study was designed in accordance with EMA (the European Medicines Agency) regulatory guidelines, with the aim of characterizing the bioavailability of olmesartan medoxomil/ hydrochlorothiazide in the two formulations (Olmesartan Medoxomil/ Hydrochlorothiazide (HCTZ), 40 mg/ 25 mg film-coated tablets (Manufacturer: Pharmtechnology LLC, Republic of Belarus) and Olmetec Plus® (Olmesartan Medoxomil/ Hydrochlorothiazide), 40 mg/25 mg film-coated tablets, (Manufacturer: Daiichi Sankyo Europe GmbH, Germany)) in healthy subjects. As this is a bioequivalence trial where each subject received each study treatment in a crossover fashion, a control group was not included. Within the clinical portion of the study each subject received a single oral dose of the test and the reference formulation in compliance with the generated randomization code. The primary study endpoints were the pharmacokinetic (PK) parameters Cmax and AUC0-t of olmesartan and hydrochlorothiazide.
This is a single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence,
crossover study design, in which 32 healthy adult subjects received one of the study
treatments during each study period.
The objective of this study is to determine the bioequivalence of two different formulations
of olmesartan medoxomil/ HCTZ after a single oral dose administration under fasting
conditions.
The intra-subject variation following a single dose of olmesartan/ HCTZ appears to be around
25% for Cmax and around 18% for AUC0-T for olmesartan and around 18% for Cmax and around 13%
for AUC0-T for HCTZ. Statistically, given that the expected Test to Reference ratio of
geometric LSmeans should fall within 95 and 105%, it is estimated that the lowest number of
subjects to meet the 80 to 125% bioequivalence range for each analyte with a statistical a
priori power of at least 80% is about 28.
Therefore, the inclusion of 32 subjects should be sufficient to account for the possibility
of drop-outs, variations around the estimated intra-subject CV and to conclude in favor of
the hypothesis of bioequivalence with sufficient statistical power. A Caucasian population
will be enrolled to minimize variability and optimize detection of differences between the
Test and Reference formulations without regard to race.
Subject eligibility for this study will be determined at the screening visit and eligible
subjects will be admitted to the clinical research unit at least 10 hours prior to drug
administration for each study period.
Standbys should be recruited and available to replace any subject who withdraws prior to the
first drug administration.
On-study drop-outs will not be replaced. Altasciences will generate the randomization code
with a computer program according to the study design, the number of subjects and the
sequence of treatment administration. The random allocation of each sequence of treatment
administration to each subject will be done in such a way that the study is balanced. Once
generated, the randomization code will be final and will not be modified. Eligible subjects
will be randomized to one of two treatment sequences. There will be two sequences in the
study: AB and BA, where A = the test product, B = the reference product (see detailed
description of A and B items in Section "Arms and Interventions").
For each study period, subjects will receive a single 40 mg/25 mg oral dose of olmesartan
medoxomil/HCTZ, under fasting conditions and undergo a 48-hour PK sample collection. Study
participants will be aware they will receive different formulations of the same drug, without
being informed which product (Test or Reference) is being administered. The date and time of
each dose will be recorded. For each subject, all scheduled postdose activities and
assessments will be performed relative to the time of study drug administration.
Subjects will fast overnight (no food or drink except water), for a minimum of 10 hours prior
to dosing. Fasting will continue for at least 4 hours following drug administration, after
which a standardized lunch will be served. A supper and a light snack will be served at
appropriate times thereafter, but not before 9 hours after dosing.
Water will be provided as needed until 1 hour predose. Water will be allowed beginning 1 hour
after the administration of the drug.
A total of 42 blood samples will be collected (1 tube of 3 mL for olmesartan and 1 tube of 3
mL for HCTZ at each time point) in each study period for PK assessments. The first blood
sample will be collected prior to drug administration while the others will be collected up
to 48 hours after drug administration.
Given that olmesartan medoxomil is rapidly and completely converted to the pharmacologically
active metabolite, olmesartan, and that no intact olmesartan medoxomil or intact side chain
medoxomil moiety have been detected in plasma1,2, olmesartan medoxomil cannot be reliably
measured. Therefore, the analytes to be measured in the study will be olmesartan and
hydrochlorothiazide. Olmesatran and HCTZ plasma concentrations will be measured according to
validated bioanalytical methods.
Subjects are to be discharged from the clinic after the 24-hour postdose PK sample
collection, and following medical approval. However, they may be advised to stay at the
clinical site for safety reasons, if judged necessary by the physician in charge. Subjects
will return to the clinic for blood collections at 48 hours postdose.
The expected terminal half-life values observed after a single oral 40 mg/25 mg dose of
olmesartan medoxomil/HCTZ film-coated tablet under fasting conditions are 8.6 hours for
olmesartan and 10.3 hours for HCTZ. To avoid any carry-over effect, a wash-out of 7 calendar
days is planned between drug administrations, corresponding to more than 16 times the
expected half-life of the moieties to be measured. The decision of which subjects will be
included in the PK analysis is to be documented by the pharmacokineticist (or delegate) and
approved by the sponsor before the start of the sample analysis by the bioanalytical
facility.
Subjects who are expected to provide evaluable PK data for both the Test and Reference
products (based on viable PK samples) will be included in the pharmacokinetic analysis.
Concentration data of the remaining subjects will be presented separately. Subjects who do
not complete the sampling schedule of one or more study periods may be included in the PK and
statistical analysis and bioequivalence determination for only the PK parameters that are
judged not to be affected by the missing sample(s).
Statistical analysis of Tmax will be based on a non-parametric approach. Statistical analysis
of all other PK parameters will be based on an Analysis of Variance (ANOVA) model. Two-sided
90% confidence interval of the ratio of geometric Least-Square means (LSmeans) obtained from
the ln transformed PK parameters will be calculated.
Statistical inference of olmesartan and HCTZ will be based on a bioequivalence approach using
the following standards: the ratio of geometric LSmeans with corresponding 90% confidence
interval calculated from the exponential of the difference between the Test and the Reference
for the ln-transformed parameters Cmax and AUC0-T should all be within the 80.00 to 125.00%
bioequivalence range.
The safety population will include all subjects who received at least one dose of one of the
IPs. Safety assessments will include vital signs, clinical laboratory tests, and AE
monitoring. Additional safety measurements may be performed at the discretion of the
investigator for reasons related to subject safety. The physician in charge will be present
at the clinical site for at least the first 4 hours following each drug administration and
will remain available at all times throughout the study.
Total study duration: up to 38 days (including screening).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03705533 -
Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State
|
Phase 1 | |
Completed |
NCT04938856 -
Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03646331 -
Bioequivalence of Imeglimin Tablet Formulations
|
Phase 1 | |
Completed |
NCT04564456 -
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05197517 -
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
|
Phase 1 | |
Completed |
NCT03702894 -
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03018015 -
Ibuprofen Bioavailability Trial With Oral Single Dose Administration.
|
Phase 1 | |
Withdrawn |
NCT02894515 -
Bioequivalence Study of Idalopirdine in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02206295 -
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
|
Phase 1 | |
Completed |
NCT01331993 -
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
|
Phase 1 | |
Completed |
NCT01260805 -
A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
|
Phase 1 | |
Recruiting |
NCT06066112 -
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
|
Phase 1 | |
Completed |
NCT05477810 -
Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions
|
Early Phase 1 | |
Completed |
NCT04546256 -
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05083325 -
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
|
Phase 1 | |
Completed |
NCT05061901 -
Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
Completed |
NCT06124560 -
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
|
Phase 1 | |
Completed |
NCT03340753 -
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
|
Phase 1 | |
Completed |
NCT04230070 -
Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product
|
Phase 1 |